35063014|t|A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.
35063014|a|BACKGROUND: Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau protein that forms fibrillar deposits in the brain. In AD, Tau pathology correlates strongly with clinical symptoms, cognitive dysfunction, and neuronal death. METHODS: We aimed to develop novel therapeutic D-amino acid peptides as Tau fibrillization inhibitors. It has been previously demonstrated that D-amino acid peptides are protease stable and less immunogenic than L-peptides, and these characteristics may render them suitable for in vivo applications. Using a phage display procedure against wild type full-length Tau (TauFL), we selected a novel Tau binding L-peptide and synthesized its D-amino acid version ISAD1 and its retro inversed form, ISAD1rev, respectively. RESULTS: While ISAD1rev inhibited Tau aggregation only moderately, ISAD1 bound to Tau in the aggregation-prone PHF6 region and inhibited fibrillization of TauFL, disease-associated mutant full-length Tau (TauFLDeltaK, TauFL-A152T, TauFL-P301L), and pro-aggregant repeat domain Tau mutant (TauRDDeltaK). ISAD1 and ISAD1rev induced the formation of large high molecular weight TauFL and TauRDDeltaK oligomers that lack proper Thioflavin-positive beta-sheet conformation even at lower concentrations. In silico modeling of ISAD1 Tau interaction at the PHF6 site revealed a binding mode similar to those known for other PHF6 binding peptides. Cell culture experiments demonstrated that ISAD1 and its inverse form are taken up by N2a-TauRDDeltaK cells efficiently and prevent cytotoxicity of externally added Tau fibrils as well as of internally expressed TauRDDeltaK. CONCLUSIONS: ISAD1 and related peptides may be suitable for therapy development of AD by promoting off-pathway assembly of Tau, thus preventing its toxicity.
35063014	8	28	D-amino acid peptide	Chemical	-
35063014	57	62	ISAD1	Chemical	-
35063014	88	106	neurotoxic disease	Disease	MESH:D020258
35063014	123	126	Tau	Gene	4137
35063014	175	194	Alzheimer's disease	Disease	MESH:D000544
35063014	196	198	AD	Disease	MESH:D000544
35063014	225	233	dementia	Disease	MESH:D003704
35063014	252	278	neurodegenerative disorder	Disease	MESH:D019636
35063014	350	352	AD	Disease	MESH:D000544
35063014	378	381	Tau	Gene	4137
35063014	437	439	AD	Disease	MESH:D000544
35063014	441	444	Tau	Gene	4137
35063014	499	520	cognitive dysfunction	Disease	MESH:D003072
35063014	526	540	neuronal death	Disease	MESH:D009410
35063014	589	610	D-amino acid peptides	Chemical	-
35063014	614	617	Tau	Gene	4137
35063014	686	707	D-amino acid peptides	Chemical	-
35063014	754	764	L-peptides	Chemical	-
35063014	905	908	Tau	Gene	4137
35063014	910	915	TauFL	Gene	4137
35063014	938	941	Tau	Gene	4137
35063014	1001	1006	ISAD1	Chemical	-
35063014	1094	1097	Tau	Gene	4137
35063014	1142	1145	Tau	Gene	4137
35063014	1171	1175	PHF6	Gene	84295
35063014	1215	1220	TauFL	Gene	4137
35063014	1260	1263	Tau	Gene	4137
35063014	1278	1283	TauFL	Gene	4137
35063014	1284	1289	A152T	ProteinMutation	tmVar:p|SUB|A|152|T;HGVS:p.A152T;VariantGroup:1;CorrespondingGene:4137;RS#:143624519;CorrespondingSpecies:9606;CA#:8617962
35063014	1291	1296	TauFL	Gene	4137
35063014	1297	1302	P301L	ProteinMutation	tmVar:p|SUB|P|301|L;HGVS:p.P301L;VariantGroup:0;CorrespondingGene:4137;RS#:63751273;CorrespondingSpecies:9606;CA#:225444
35063014	1337	1340	Tau	Gene	4137
35063014	1363	1368	ISAD1	Chemical	-
35063014	1373	1381	ISAD1rev	Chemical	-
35063014	1435	1440	TauFL	Gene	4137
35063014	1484	1494	Thioflavin	Chemical	MESH:C009462
35063014	1586	1589	Tau	Gene	4137
35063014	1609	1613	PHF6	Gene	84295
35063014	1676	1680	PHF6	Gene	84295
35063014	1742	1747	ISAD1	Chemical	-
35063014	1785	1788	N2a	CellLine	CVCL:0470
35063014	1831	1843	cytotoxicity	Disease	MESH:D064420
35063014	1864	1867	Tau	Gene	4137
35063014	2007	2009	AD	Disease	MESH:D000544
35063014	2047	2050	Tau	Gene	4137
35063014	2072	2080	toxicity	Disease	MESH:D064420
35063014	Association	MESH:D020258	4137
35063014	Association	MESH:D003072	4137
35063014	Association	MESH:D009410	4137
35063014	Association	MESH:D000544	4137
35063014	Association	4137	84295

